Andrew Baum
Stock Analyst at Citigroup
(2.90)
# 1,560
Out of 4,784 analysts
62
Total ratings
72.09%
Success rate
13.13%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Buy | $125 → $115 | $89.23 | +28.88% | 13 | Feb 5, 2025 | |
| PFE Pfizer | Maintains: Neutral | $30 → $29 | $25.21 | +15.03% | 10 | Jan 28, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $65 | $60.02 | +8.30% | 11 | Jan 28, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $31.37 | +27.51% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $205.29 | +4.73% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $822.51 | +8.81% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $9.55 | +4.71% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $38.74 | - | 2 | Jul 5, 2017 |
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $125 → $115
Current: $89.23
Upside: +28.88%
Pfizer
Jan 28, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $25.21
Upside: +15.03%
Bristol-Myers Squibb Company
Jan 28, 2025
Maintains: Neutral
Price Target: $60 → $65
Current: $60.02
Upside: +8.30%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $31.37
Upside: +27.51%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $205.29
Upside: +4.73%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $822.51
Upside: +8.81%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $9.55
Upside: +4.71%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $38.74
Upside: -